Mekrazym (Amylase, Lipase, Protease)

Amylase breaks down complex carbohydrates into simple sugars, lipase hydrolyzes dietary fats into fatty acids and monoglycerides, and protease cleaves protein molecules into amino acids and small peptides. By providing these enzymes directly to the gut, Mekrazym compensates for reduced endogenous secretion and promotes more complete nutrient absorption.

The appropriate dose of Mekrazym is individualized and must be determined by a qualified healthcare professional based on the patient’s specific condition, severity of enzyme deficiency, and dietary intake. Patients should follow the prescriber’s instructions and not alter the dosing regimen without medical advice.

Safety data for Mekrazym in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any possible risk to the fetus or infant. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss use with their obstetrician or healthcare provider.

To request Mekrazym, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Mekrazym combines three key enzymes—amylase, lipase and protease—in a single oral formulation, offering broad macronutrient coverage. Compared with products that contain only lipase or a limited enzyme mix, Mekrazym may provide more comprehensive digestion support, especially when patients have mixed carbohydrate, fat and protein malabsorption.

Store Mekrazym at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture, excessive heat and direct sunlight. Do not refrigerate or freeze unless the label specifically advises otherwise.

Mekrazym is taken orally, usually with meals or snacks that contain the nutrients to be digested. The tablets or capsules should be swallowed whole with a glass of water unless the prescribing information indicates otherwise.

The most serious risks include allergic reactions that may manifest as rash, swelling, difficulty breathing or anaphylaxis, and rare cases of severe abdominal pain or pancreatitis exacerbation. Patients should seek immediate medical attention if they experience any signs of a serious hypersensitivity reaction or persistent severe gastrointestinal symptoms.

Mekrazym should be avoided by individuals with known hypersensitivity to any of its enzyme components, those who have experienced severe allergic reactions to similar enzyme products, and patients with active pancreatitis unless directed by a physician. Consultation with a healthcare professional is essential before starting therapy.